The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release from Johnson & Johnson.
Medical Device Network on MSN
FDA approves J&J’s TECNIS PureSee intraocular lens
The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA approval for its ...
Please provide your email address to receive an email when new articles are posted on . Combining extended depth of focus and trifocal IOLs improves distance vision without sacrificing near. A ...
JACKSONVILLE, Fla., March 12, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) ...
FDA has approved Johnson & Johnson's Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The new IOL will be available to U.S. patients ...
(RTTNews) - Eye care firm Alcon Inc.(ALC) announced Tuesday that Vivity, an extended depth of focus or EDOF intraocular lens or IOL, is now available on the company's most advanced lens ...
FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
Add Yahoo as a preferred source to see more of our stories on Google. The approval adds to J&J’s surgical vision portfolio Johnson & Johnson (J&J) has received approval from the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results